Showing 581 - 600 results of 2,004 for search '"Breast cancer"', query time: 0.09s Refine Results
  1. 581

    Intra-tumoral sphingobacterium multivorum promotes triple-negative breast cancer progression by suppressing tumor immunosurveillance by Zhikai Mai, Liwu Fu, Jiyan Su, Kenneth K.W. To, Chuansheng Yang, Chenglai Xia

    Published 2025-01-01
    “…Conclusions This study reveals S. multivorum suppresses immune surveillance within the TME, thereby promoting breast cancer progression.…”
    Get full text
    Article
  2. 582
  3. 583
  4. 584

    Third Swiss Annual Meeting on HER2-Positive Breast Cancer: Recent Advances and New Challenges by Marcus Vetter, Christian Kurzeder

    Published 2024-09-01
    “…The development of antibody-based therapies has transformed the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. More recently, HER2-directed antibody-drug conjugates (ADCs) have demonstrated efficacy in HER2-negative breast cancer patients who had a certain level of HER2 expression (HER2 low). …”
    Get full text
    Article
  5. 585
  6. 586
  7. 587

    Protocol to study the impact of breast cancer on colonization resistance of mouse microbiota using network node manipulation by Ana Laura Cano-Argüelles, Alejandra Wu-Chuang, Lourdes Mateos-Hernandez, Lianet Abuin-Denis, Apolline Maitre, Janet Avellanet, Arlem García, Dasha Fuentes, Alejandro Cabezas-Cruz

    Published 2025-03-01
    “…We present a protocol to study the gut microbial community in a mouse model of breast cancer using a network-based approach. Here, we describe the procedures for tumor cell production and inoculation and 16S rRNA data processing. …”
    Get full text
    Article
  8. 588

    Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation by Farnaz Khaleseh, Abbas Hemmati Azandaryani, Fatemeh Fathian Kolahkaj, Mozafar Khazaei, Katayoun Derakhshandeh

    Published 2021-05-01
    “…Abstract Epirubicin (EPI) is one of the potent breast cancer (BC) chemotherapeutic agents, but its adverse effects limit its efficacy. …”
    Get full text
    Article
  9. 589

    Prevalence and Associated Factors of Anemia among Breast Cancer Patients Undergoing Chemotherapy: A Prospective Study by Fares M.S Muthanna, Mahmathi Karuppannan, Egbal Abdulrahman, Suriyon Uitrakul, Bassam Abdul Hassan Rasool, Ali Haider Mohammed

    Published 2022-01-01
    “…The purpose of this study was to ascertain the prevalence and factors associated with anemia (hemoglobin [Hb] 12 g/dL) in breast cancer patients undergoing chemotherapy. Materials and Methods. …”
    Get full text
    Article
  10. 590
  11. 591
  12. 592

    Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer by Sara M Tolaney, Tianyu Li, Edward T Richardson, Judith Agudo, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Adrienne G Waks, Tanya E Keenan, Nabihah Tayob, Gerburg M Wulf, Victoria Attaya, Leilani Anderson, Ian E Krop, Eliezer M Van Allen

    Published 2022-10-01
    “…The safety and tolerability of trastuzumab emtansine (T-DM1) combined with pembrolizumab is unknown.Methods This was a single-arm phase Ib trial (registration date January 26, 2017) of T-DM1 plus pembrolizumab in metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Eligible patients had HER2-positive, metastatic breast cancer previously treated with taxane, trastuzumab, and pertuzumab, and were T-DM1-naïve. …”
    Get full text
    Article
  13. 593
  14. 594
  15. 595
  16. 596
  17. 597
  18. 598

    The Effect of PT Link and Waterbath Antigenic Retrieval Procedures On The Expression of Common Receptors In Breast Cancer Cases by Ahmed Abdelbadie, Elsadig Ahmed Adam, Manar Abdelrahman

    Published 2017-05-01
    “…Materials and Method: FFPEB from cases diagnosed as breast cancer were examined for the expression of estrogen- receptor (ER), progesterone receptor (PR) and HER2 by immunohistochemical techniques using two different AR methods. …”
    Get full text
    Article
  19. 599
  20. 600

    Circulating Tumor DNA in a Breast Cancer Patient's Plasma Represents Driver Alterations in the Tumor Tissue by Jieun Lee, Sung-Min Cho, Min Sung Kim, Sug Hyung Lee, Yeun-Jun Chung, Seung-Hyun Jung

    Published 2017-03-01
    “…In this study, we performed whole-exome sequencing for a breast cancer tissue and identified PTEN p.H259fs*7 frameshift mutation. …”
    Get full text
    Article